Among postmenopausal women, the incidence of ER+ breast cancer correlates with age at menopause9 and with blood oestrogen levels,12 and randomised trials have shown that the incidence of ER+ breast cancer can be greatly reduced by anti-oestrogen drugs such as an aromatase inhibitor, or tamoxifen. The gene discussed is CYP19A1; the disease is breast cancer.